{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T01:38:34Z","timestamp":1777513114545,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T00:00:00Z","timestamp":1525219200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1038\/s41391-018-0036-y","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T09:53:44Z","timestamp":1525254824000},"page":"403-410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8381-5253","authenticated-orcid":false,"given":"Huah Shin","family":"Ng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogda","family":"Koczwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Roder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"Vitry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,2]]},"reference":[{"key":"36_CR1","unstructured":"Australian Government Cancer Australia. Prostate cancer statistics. Australian Government Cancer Australia. 2017. https:\/\/prostate-cancer.canceraustralia.gov.au\/statistics . Accessed 21 Sept 2017."},{"key":"36_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10552-005-0530-0","volume":"17","author":"PD Baade","year":"2006","unstructured":"Baade PD, Fritschi L, Eakin EG. Non-cancer mortality among people diagnosed with cancer (Australia). Cancer Causes Control. 2006;17:287\u201397.","journal-title":"Cancer Causes Control"},{"key":"36_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3322\/caac.21234","volume":"64","author":"TA Skolarus","year":"2014","unstructured":"Skolarus TA, Wolf AMD, Erb NL, Brooks DD, Rivers BM, Underwood W, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin. 2014;64:225\u201349.","journal-title":"CA Cancer J Clin"},{"key":"36_CR4","unstructured":"Australian Institute of Health and Welfare. Australia\u2019s health 2014. Australia\u2019s health series no. 14. Cat. no. AUS 178. Canberra: AIHW; 2014. http:\/\/www.aihw.gov.au\/publication-detail\/?id=60129547205 . Accessed 10 Oct 2017."},{"key":"36_CR5","unstructured":"Macmillan Cancer Support, National Cancer Intelligence Network (NCIN), Monitor Deloitte. Routes from diagnosis: the most detailed map of cancer survivorship yet. United Kingdom: Macmillan Cancer Support; 2014. http:\/\/www.macmillan.org.uk\/about-us\/what-we-do\/evidence\/cancer-intelligence\/routes-from-diagnosis.html . Accessed 14 Sept 2017."},{"key":"36_CR6","doi-asserted-by":"publisher","first-page":"v69","DOI":"10.1093\/annonc\/mdv222","volume":"26","author":"C Parker","year":"2015","unstructured":"Parker C, Gillessen S, Heidenreich A, Horwich A, on behalf of the ESMO Guidelines Committee. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v69\u2013v77.","journal-title":"Ann Oncol"},{"key":"36_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/bju.13969","volume":"120","author":"WL Ong","year":"2017","unstructured":"Ong WL, Foroudi F, Evans S, Millar J. Large institutional variations in use of androgen deprivation therapy with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer. BJU Int. 2017;120:35\u201342.","journal-title":"BJU Int"},{"key":"36_CR8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5694\/j.1326-5377.2011.tb02979.x","volume":"194","author":"M Grossmann","year":"2011","unstructured":"Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL, Zajac JD. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy. Med J Aust. 2011;194:301\u20136.","journal-title":"Med J Aust"},{"key":"36_CR9","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/cncr.22933","volume":"110","author":"CS Saigal","year":"2007","unstructured":"Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110:1493\u20131500.","journal-title":"Cancer"},{"key":"36_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jnci\/djp404","volume":"102","author":"NL Keating","year":"2010","unstructured":"Keating NL, O\u2019Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102:39\u201346.","journal-title":"J Natl Cancer Inst"},{"key":"36_CR11","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.eururo.2013.02.002","volume":"65","author":"CG Jespersen","year":"2014","unstructured":"Jespersen CG, Norgaard M, Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol. 2014;65:704\u20139.","journal-title":"Eur Urol"},{"key":"36_CR12","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.urology.2007.08.012","volume":"70","author":"MJ Lage","year":"2007","unstructured":"Lage MJ, Barber BL, Markus RA. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology. 2007;70:1104\u20138.","journal-title":"Urology"},{"key":"36_CR13","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/j.1464-410X.2009.08483.x","volume":"104","author":"VK Wadhwa","year":"2009","unstructured":"Wadhwa VK, Weston R, Mistry R, Parr NJ. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int. 2009;104:800\u20135.","journal-title":"BJU Int"},{"key":"36_CR14","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMoa041943","volume":"352","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo Y-F, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154\u201364.","journal-title":"N Engl J Med"},{"key":"36_CR15","unstructured":"Australian Government Department of Health. Australian statistics on medicines 2011. Department of Health. 2013. http:\/\/www.pbs.gov.au\/info\/statistics\/asm\/asm-2011 . Accessed 10 Nov 2017."},{"key":"36_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-015-1616-8","volume":"8","author":"L Mellish","year":"2015","unstructured":"Mellish L, Karanges EA, Litchfield MJ, Schaffer AL, Blanch B, Daniels BJ, et al. The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers. BMC Res Notes. 2015;8:634.","journal-title":"BMC Res Notes"},{"key":"36_CR17","first-page":"761","volume":"41","author":"KL Sloan","year":"2003","unstructured":"Sloan KL, Sales AE, Liu CF, Fishman P, Nichol P, Suzuki NT, et al. Construction and characteristics of the RxRisk-V: a VA-adapted pharmacy-based case-mix instrument. Med Care. 2003;41:761\u201374.","journal-title":"Med Care"},{"key":"36_CR18","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1753-6405.2009.00357.x","volume":"33","author":"A Vitry","year":"2009","unstructured":"Vitry A, Wong SA, Roughead EE, Ramsay E, Barratt J. Validity of medication-based co-morbidity indices in the Australian elderly population. Aust N Z J Public Health. 2009;33:126\u201330.","journal-title":"Aust N Z J Public Health"},{"key":"36_CR19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jclinepi.2010.02.015","volume":"64","author":"CY Lu","year":"2011","unstructured":"Lu CY, Barratt J, Vitry A, Roughead E. Charlson and Rx-Risk comorbidity indices were predictive of mortality in the Australian health care setting. J Clin Epidemiol. 2011;64:223\u20138.","journal-title":"J Clin Epidemiol"},{"key":"36_CR20","unstructured":"Australian Institute of Health and Welfare. Australian burden of disease study: impact and causes of illness and death in Australia 2011. Australian burden of disease study series no. 3. BOD 4. Canberra: AIHW; 2016. https:\/\/www.aihw.gov.au\/reports\/burden-of-disease\/australian-burden-of-disease-study-impact-and-causes-of-illness-and-death-in-australia-2011\/contents\/highlights . Accessed 14 Sept 2017."},{"key":"36_CR21","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1016\/j.ejca.2010.07.035","volume":"46","author":"NF Khan","year":"2010","unstructured":"Khan NF, Ward AM, Watson E, Rose PW. Consulting and prescribing behaviour for anxiety and depression in long-term survivors of cancer in the UK. Eur J Cancer. 2010;46:3339\u201344.","journal-title":"Eur J Cancer"},{"key":"36_CR22","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/pds.3753","volume":"24","author":"SA Pearson","year":"2015","unstructured":"Pearson SA, Abrahamowicz M, Srasuebkul P, Buckley NA. Antidepressant therapy in cancer patients: initiation and factors associated with treatment. Pharmacoepidemiol Drug Saf. 2015;24:600\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"36_CR23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1017\/S104161021400218X","volume":"27","author":"PM Chen","year":"2015","unstructured":"Chen PM, Chen SC, Liu CJ, Hung MH, Tsai CF, Hu YW, et al. The association between prostate cancer and mood disorders: a nationwide population-based study in Taiwan. Int Psychogeriatr. 2015;27:481\u201390.","journal-title":"Int Psychogeriatr"},{"key":"36_CR24","first-page":"S37","volume":"7","author":"RJ Kumar","year":"2005","unstructured":"Kumar RJ, Barqawi A, Crawford ED. Adverse events associated with hormonal therapy for prostate cancer. Rev Urol. 2005;7:S37\u2013S43.","journal-title":"Rev Urol"},{"key":"36_CR25","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1002\/cncr.24283","volume":"115","author":"LG Taylor","year":"2009","unstructured":"Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer. 2009;115:2388\u201399.","journal-title":"Cancer"},{"key":"36_CR26","doi-asserted-by":"publisher","first-page":"e0173266","DOI":"10.1371\/journal.pone.0173266","volume":"12","author":"SD Chung","year":"2017","unstructured":"Chung S-D, Kao L-T, Lin H-C, Xirasagar S, Huang C-C, Lee H-C. Patients receiving androgen deprivation therapy for prostate cancer have an increased risk of depressive disorder. PLoS ONE. 2017;12:e0173266.","journal-title":"PLoS ONE"},{"key":"36_CR27","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1200\/JCO.2015.64.1969","volume":"34","author":"KT Dinh","year":"2016","unstructured":"Dinh KT, Reznor G, Muralidhar V, Mahal BA, Nezolosky MD, Choueiri TK, et al. Association of androgen deprivation therapy with depression in localized prostate cancer. J Clin Oncol. 2016;34:1905\u201312.","journal-title":"J Clin Oncol"},{"key":"36_CR28","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","volume":"87","author":"MR Smith","year":"2002","unstructured":"Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87:599\u2013603.","journal-title":"J Clin Endocrinol Metab"},{"key":"36_CR29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/pcan.2015.50","volume":"19","author":"K Mitsuzuka","year":"2016","unstructured":"Mitsuzuka K, Kyan A, Sato T, Orikasa K, Miyazato M, Aoki H, et al. Influence of 1 year of androgen deprivation therapy on lipid and glucose metabolism and fat accumulation in Japanese patients with prostate cancer. Prostate Cancer Prostatic Dis. 2016;19:57\u201362.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"36_CR30","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1016\/j.juro.2009.01.047","volume":"181","author":"PJ Saylor","year":"2009","unstructured":"Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2009;181:1998\u20132008.","journal-title":"J Urol"},{"key":"36_CR31","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.1200\/JCO.2008.18.4184","volume":"26","author":"F Saad","year":"2008","unstructured":"Saad F, Adachi JD, Brown JP, Canning LA, Gelmon KA, Josse RG, et al. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol. 2008;26:5465\u201376.","journal-title":"J Clin Oncol"},{"key":"36_CR32","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/jdi.12472","volume":"7","author":"H Wang","year":"2016","unstructured":"Wang H, Sun X, Zhao L, Chen X, Zhao J. Androgen deprivation therapy is associated with diabetes: evidence from meta\u2010analysis. J Diabetes Investig. 2016;7:629\u201336.","journal-title":"J Diabetes Investig"},{"key":"36_CR33","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.urology.2006.11.002","volume":"69","author":"J Morote","year":"2007","unstructured":"Morote J, Morin JP, Orsola A, Abascal JM, Salvador C, Trilla E, et al. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology. 2007;69:500\u20134.","journal-title":"Urology"},{"key":"36_CR34","first-page":"129","volume":"7","author":"JF Lester","year":"2015","unstructured":"Lester JF, Mason MD. Cardiovascular effects of hormone therapy for prostate cancer. Drug Healthc Patient Saf. 2015;7:129\u201338.","journal-title":"Drug Healthc Patient Saf"},{"key":"36_CR35","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1001\/jama.2011.1745","volume":"306","author":"PL Nguyen","year":"2011","unstructured":"Nguyen PL, Je Y, Schutz FB, Hoffman KE, Hu JC, Parekh A, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011;306:2359\u201366.","journal-title":"JAMA"},{"key":"36_CR36","doi-asserted-by":"crossref","first-page":"176","DOI":"10.5694\/j.1326-5377.2006.tb00180.x","volume":"184","author":"DJ Holmes-Walker","year":"2006","unstructured":"Holmes-Walker DJ, Woo H, Gurney H, Do VT, Chipps DR. Maintaining bone health in patients with prostate cancer. Med J Aust. 2006;184:176\u20139.","journal-title":"Med J Aust"},{"key":"36_CR37","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","volume":"133","author":"N Bhatia","year":"2016","unstructured":"Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans A, et al. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer. Circulation. 2016;133:537\u201341.","journal-title":"Circulation"},{"key":"36_CR38","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1200\/JCO.2014.60.2557","volume":"33","author":"MJ Resnick","year":"2015","unstructured":"Resnick MJ, Lacchetti C, Bergman J, Hauke RJ, Hoffman KE, Kungel TM, et al. Prostate cancer survivorship care guideline: American Society of Clinical Oncology Clinical Practice Guideline endorsement. J Clin Oncol. 2015;33:1078\u201385.","journal-title":"J Clin Oncol"},{"key":"36_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.prnil.2015.08.001","volume":"4","author":"D Parikesit","year":"2016","unstructured":"Parikesit D, Mochtar CA, Umbas R, Hamid ARAH. The impact of obesity towards prostate diseases. Prostate Int. 2016;4:1\u20136.","journal-title":"Prostate Int"},{"key":"36_CR40","unstructured":"Paez Borda A, Charnay-Sonnek F, Fonteyne V, Papaioannou E. Guidelines on pain management & palliative care. European Association of Urology. 2013. https:\/\/uroweb.org\/wp-content\/uploads\/25-Pain-Management_LR.pdf . Accessed 25 July 2017."},{"key":"36_CR41","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/andr.12187","volume":"4","author":"SD Chung","year":"2016","unstructured":"Chung SD, Lin HC, Tsai MC, Kao LT, Huang CY, Chen KC. Androgen deprivation therapy did not increase the risk of Alzheimer\u2019s and Parkinson\u2019s disease in patients with prostate cancer. Andrology. 2016;4:481\u20135.","journal-title":"Andrology"},{"key":"36_CR42","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/pcan.2017.10","volume":"20","author":"KT Nead","year":"2017","unstructured":"Nead KT, Sinha S, Nguyen PL. Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2017;20:259\u201364.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"36_CR43","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/13685538.2016.1271782","volume":"20","author":"JH Jhan","year":"2017","unstructured":"Jhan JH, Yang YH, Chang YH, Guu SJ, Tsai CC. Hormone therapy for prostate cancer increases the risk of Alzheimer\u2019s disease: a nationwide 4-year longitudinal cohort study. Aging Male. 2017;20:33\u201338.","journal-title":"Aging Male"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41391-018-0036-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-018-0036-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-018-0036-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:33:05Z","timestamp":1684618385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-018-0036-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,2]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["36"],"URL":"https:\/\/doi.org\/10.1038\/s41391-018-0036-y","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,2]]},"assertion":[{"value":"10 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}